PEALut in the Dietary Management of Patients with Acute Ischemic Stroke: A Prospective Randomized Controlled Clinical Trial
Controlled trialHumansWith luteolin (co-ultramicronised palmitoylethanolamide and luteolin, PEALut)
This study tested palmitoylethanolamide together with luteolin (co-ultramicronised palmitoylethanolamide and luteolin, PEALut). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Controlled trial
- Subjects
- 60 patients with acute ischaemic stroke treated with thrombolysis; 30 received PEALut plus standard therapy
- Dose used in the study
- PEALut 770 mg twice daily in addition to standard therapy
- Duration
- 90 days
- What was measured
- Neurological deficit (NIHSS), independence in daily living (Barthel Index), disability (modified Rankin Scale) and cognition (MMSE, MoCA).
What the authors reported
This prospective randomized controlled trial found:
- In all patients NIHSS severity moved from moderate to minor (p < 0.0001).
- Barthel Index and modified Rankin Scale improved over time with a difference in favour of PEALut (p < 0.002 for BI, p < 0.0001 for mRS).
- The PEALut group also showed a marked improvement in MMSE and MoCA.
- PEALut was reported safe in this setting.
Limits of this study
A small trial of 60 people. The abstract does not mention a placebo or blinding, so the comparison was against standard therapy alone. Effect sizes for cognition are not given. The authors declare no conflict of interest.
Source
PubMed 38256644 · doi:10.3390/jcm13020509
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.